HepaRx
Small Molecule Cancer Drugs
Health Tech & Life Sciences
Non Active, Jul 2018 ceased to operate
Company Overview
Snapshot
Founded in September 2014, HepaRx operated with 1–10 employees. The company secured funding across one round from FutuRx. In May 2017, HepaRx received investment from FutuRx, an incubator focused on biotech startups.
Business overview
HepaRx is a Health Tech & Life Sciences company specializing in the development of small molecule cancer drugs. The company’s core technology focuses on inhibiting heparanase (Hpa) enzymatic activity to prevent the spread of cancer cells. Utilizing the Hpa crystal structure for drug design, HepaRx targets various cancer types, including pancreatic, lung, breast, and mesothelioma, operating within the Pharmaceuticals & Diagnostics sector.
Log in to access full profile ›Company Intelligence Q&A
- What is HepaRx's primary focus?
- HepaRx is focused on developing small molecule cancer drugs that inhibit heparanase (Hpa) enzymatic activity to stop the spread of cancer cells.
- When was HepaRx founded?
- HepaRx was founded in September 2014.
- What is the status of HepaRx?
- HepaRx is currently non-active, having ceased operations in July 2018.
- What technology does HepaRx employ for drug development?
- HepaRx employs the Hpa crystal structure for drug design and development, targeting the enzyme heparanase which is involved in cancer progression.